Log In
BCIQ
Print this Print this
 

oral CBL0137 (formerly Curaxin CBLC137)

  Manage Alerts
Collapse Summary General Information
Company Cleveland BioLabs Inc.
DescriptionNext-generation Curaxin anticancer compound which targets p53, NF-kappa B (NF-kB) and heat shock transcription factor 1 (HSF1)
Molecular Target Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50) ; p53
Mechanism of ActionNF-kappa B (NF-kB) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$15.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2009

$15.0M

Undisclosed

0

Get a free BioCentury trial today